X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

    Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

    INOVIO to Develop dMAb COVID Treatments under DARPA Grant

    Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

    Thermo Fisher Expands Clinical Supply Services in Europe

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    Allergy Alarm Raised On Pfizer-BioNTech COVID-19 Vaccine

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    U.S. FDA confirms Pfizer COVID vaccine safe & effective

    Abzena Invests $60M Into cGMP Manufacturing Capacity

    COVID-19 Vaccine – Has UK created the pressure to rush on other countries?

    The UK begins the biggest ever immunization program

    The UK begins the biggest ever immunization program

    Russia roll out the homegrown Sputnik V vaccine for its population

    Russia roll out the homegrown Sputnik V vaccine for its population

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Vertex Pharmaceuticals to buy US firm Exonics Therapeutics

Content Team by Content Team
17th June 2019
in Market Moves
vertex acquired

Vertex Pharmaceuticals has signed an agreement to acquire US-based Exonics Therapeutics in a deal valued up to $1bn (£787m).

Under the deal, Exonics equity holders will receive $245m (£192m) upfront payment from Vertex, as well as potential future payments based on the achievement of specified development and regulatory milestones for the Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) programmes.

Based in Watertown of Massachusetts, Exonics Therapeutics is involved in the development of gene editing therapies for the treatment of patients with DMD and other severe genetic neuromuscular diseases.

Exonics has used SingleCut CRISPR to genetically repair and restore dystrophin in multiple small and large animal DMD preclinical models.

Exonics’ technology, which is licensed from UT Southwestern Medical Center, is based on the research of Dr. Olson.

Subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, the deal is expected to be completed in the third quarter of this year.

Vertex chairman, president and CEO Dr Jeffrey Leiden said: “Through the expanded collaboration with CRISPR and the acquisition of Exonics, we are bringing together the intellectual property, technologies, and scientific expertise needed to establish a leading gene editing platform for DMD and DM1.”

Vertex has also expanded its collaboration with CRISPR Therapeutics to discover and develop gene editing therapies for the treatment of DMD and DM1.

As per terms of the deal, Vertex will pay $175m (£137m) upfront for the exclusive worldwide rights to CRISPR Therapeutics’ existing and future intellectual property, including foundational CRISPR/Cas9 technology, novel endonucleases, single and double cut guide RNAs, and AAV vectors for DMD and DM1 gene editing products.

Vertex will take responsibility for all other research, development, manufacturing, and commercialisation costs.

CRISPR Therapeutics will secure payments of up to $1bn (£787m) , including the upfront and potential future payments, based on the achievement of specified research, development, regulatory, and commercial milestones for the DMD and DM1 programmes.

Vertex will also pay tiered royalties on future net sales on any products, which may result from this collaboration.

Previous Post

ProtoKinetix achieves primary objective safety at midpoint of clinical trial

Next Post

LYNPARZA delivers 72per ORR in phase 3 SOLO3 trial in advanced ovarian cancer

Related Posts

Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

3rd December 2020
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Antares Vision acquires pharma packaging leak specialist for $17.9m

20th July 2020
UCB Acquires Engage Therapeutics for $125M
Market Moves

UCB Acquires Engage Therapeutics for $125M

8th June 2020
Sygnature expands capabilities with acquisition of Alderley Oncology
Market Moves

Sygnature expands capabilities with acquisition of Alderley Oncology

4th June 2020
Sandoz Completes Acquisition of Aspens Japanese Operations
Market Moves

Sandoz Completes Acquisition of Aspens Japanese Operations

5th February 2020
Novartis to acquire The Medicines Company for USD 9.7 bn
Market Moves

Novartis to acquire The Medicines Company for USD 9.7 bn

26th November 2019
Next Post
SOLO3

LYNPARZA delivers 72per ORR in phase 3 SOLO3 trial in advanced ovarian cancer

Latest News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021
News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

17th December 2020
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Drug Development

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

17th December 2020
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery
Drug Development

Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery

17th December 2020
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
Drug Development

INOVIO to Develop dMAb COVID Treatments under DARPA Grant

17th December 2020
Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing
Clinical Trials

Thermo Fisher Expands Clinical Supply Services in Europe

17th December 2020
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In